Skip to main content
Premium Trial:

Request an Annual Quote

ProGenTech Grabs $21M in Venture Financing from US, China Investors

NEW YORK (GenomeWeb News) – ProGenTech said today it has raised $21 million in a round of Series C financing led by Bay City Capital of San Francisco and DT Capital of Shanghai. 
ProGenTech, which makes an automated nucleic acid extraction and purification system, has headquarters in Emeryville, Calif., and in Shanghai.
The company also said that it has appointed Trevor Hawkins to be chairman and CEO of the company. Hawkins worked on the development of a magnetic bead technology used by several biotech companies. He formerly was CEO of Philips Molecular Healthcare and was an executive at GE and at MDS. Hawkins also was the director of the US Department of Energy’s Joint Genome Institute when it was working on sequencing the human genome.
Earlier financing for ProGenTech came from angel investors. The Series C funding marks the first round of financing from institutional venture capital firms.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.